Published December 2016. This issue of ExpertREACT covers key vaccine industry press releases and milestones from across 2016. VacZine Analytics' travel vaccine intelligence is available in VAMV068 (Zika vaccines) and VAMV090 (new travel vaccines).
2016: Key Milestones Month by Month
The following is a record of significant vaccine industry press releases and regulatory milestones from 2016, as tracked by VacZine Analytics.
January
- Sanofi signs an agreement with the Human Vaccine Project Inc
February
- Sanofi launches Zika vaccine project
- GSK announces US regulatory submission seeking expanded indication for FluLaval® Quadrivalent (Influenza Vaccine) for infants 6 months and over
March
- Sanofi Pasteur and Merck (known as MSD outside the United States and Canada) announce intent to end joint vaccines operations in Europe, Sanofi Pasteur MSD (SPMSD), to pursue their own distinct growth strategies
April
- Sanofi's Dengvaxia® is used in the world's first public immunisation programme against dengue in three highly endemic areas of the Philippines (1 million school children)
- The WHO SAGE committee recommends use of Dengvaxia®
May
- GSK reports Phase IIIb study (V72_28) indicating a new 2+1 infant schedule for meningococcal group B vaccine
- Pfizer announces EMA acceptance for review of marketing authorisation application for TRUMENBA® (Meningococcal Group B Vaccine)
- Pfizer presents results from two Phase 3 TRUMENBA® studies at the ESPID meeting
June
- Merck releases systematic review of 58 publications of real-world use of Gardasil presented at EUROGIN Congress
- Pfizer receives European approval for new multi-dose vial presentation of Prevenar 13®
- Takeda initiates first norovirus vaccine field trial
July
- Pfizer receives FDA approval for Prevnar 13® in adults aged 18 through 49
- Sanofi signs research agreement for Zika vaccine project with WRAIR
- GSK publishes high efficacy Phase III data for Shingrix™ in the New England Journal of Medicine
Dengvaxia® first-year commercial sales - disappointing relative to expectations given approval in 14 countries. WHO SAGE's restrictive '>9 years, high seroprevalence' recommendation limited national programme uptake.
August
- Sanofi's Dengvaxia® used in public vaccination programme in Paraná state of Brazil for 30 highly affected municipalities
September
- GSK publishes further high-efficacy Phase III data for Shingrix™ in the New England Journal of Medicine
- Sanofi's Dengvaxia® available in private clinics in Mexico
- BARDA grants $43.2m to Sanofi Pasteur for Zika vaccine development
- Takeda initiates Phase III TIDES trial for dengue candidate TAK-003
- Takeda agrees to develop Zika vaccine with up to $312 million from the US government
October
- GSK announces US regulatory submission for Shingrix™ (aged 50 years and over)
- Pfizer announces CDC ACIP votes to recommend new dosing schedule(s) for TRUMENBA®
- Sanofi Pasteur agrees to collaborate with WRAIR and Fiocruz on Zika project
November
- GSK announces EU regulatory submission for Shingrix™ (aged 50 years and over)
- GSK receives FDA approval for FluLaval QIV (aged 6 months and over)
- Pfizer's Prevenar 13® receives approval for use in infants and children in China
- Takeda to invest more than 100 million euros in German dengue manufacturing plant
"Dengvaxia's first year has been disappointing, but the WHO SAGE 'real use' experience from Brazil and the Philippines may yet elevate country adoption - just as it did for Bexsero."
Outlook for 2017
The year 2016 was defined by flavivirus vaccines: Dengvaxia's rocky commercial debut and the mobilisation of significant R&D resources against Zika. Takeda's CAPEX commitment to a dengue manufacturing plant and the Phase III initiation of TAK-003 signal that Sanofi's window of exclusivity in the dengue space may be shorter than the company hoped. For the industry, the pivotal question entering 2017 is whether real-world effectiveness data from the Philippines and Brazil will unlock a broader dengue market - or whether Dengvaxia's restrictive label remains an insurmountable barrier to national programme adoption.
This article is available in VacZine Analytics' Expert News archive as published in December 2016. Sources: corporate press releases as cited.